Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM‐042 [(E)‐4‐(2‐(2‐(5,8‐dimethyl‐[1,2,4]triazolo[1,5‐a]pyrazin‐2‐yl)vinyl)‐6‐(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)morpholine] in rats: potential for the treatment of schizophrenia

DOI: 10.1002/prp2.241

Keywords: Antipsychotics, catalepsy, occupancy, PDE10A, PDM‐042, schizophrenia

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text